🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Open Access: A medical claims database analysis finds no difference in the risk of vascular events in patients with #migraine treated with #erenumab vs other #CGRP mAbs vs #onabotulinumtoxinA …adachejournal.onlinelibrary.wiley.com/doi/full/10.11… David Dodick et al

Serum levels of #autotaxin are found to be elevated in people with #migraine & chronic migraine, suggesting its role as a novel biomarker & potential treatment target …adachejournal.onlinelibrary.wiley.com/doi/full/10.11… Alberto Ouro PhD, Mariña Rodríguez-Arrizabalaga et al Instituto de Invest. Sanitaria de Santiago (IDIS)

Traditionally, progression = episodic → chronic migraine (4.7%). But new definitions show higher rates: - 9.6% had ≥5 more headache days - 21.7% had increased disability (MIDAS +5) This expanded view could reshape ICHD classification! Link to our study 👉rb.gy/xlcp7n

A recent systematic review & meta-analysis failed to identify a correlation between #hypertension & #erenumab, & recommends additional studies, especially in high-risk groups …adachejournal.onlinelibrary.wiley.com/doi/full/10.11… Luana Miyahira Makita et al

❤️❤️

Just arrived San Diego for #AANAM !

Timeline of discovery of antibodies associated with autoimmune encephalitis. #AANAM from dr. Brian weinshenker.

Thanks for the interview during #AANAM .

An excellent presentation ⁦Jr Wei Wu, MD⁩ on #BrainFog #Headache #LongCovid and possible connection to vascular changes #AANAM ⁦American Academy of Neurology⁩ 🧠 ⁦Cephalalgia⁩ ⁦Cephalalgia Reports⁩ ⁦International Headache Society⁩ 🧠⁦Amy Hessler⁩ ⁦⁦American Headache Society⁩

A daily schedule during the #AANAM: conference center-> aircraft carrier-> conference center-> swing and slides 😆😆

Honored to present our new findings on post-#COVID headache and brain fog at this year’s #AANAM in #SanDiego. Grateful for our team members’ efforts and hope the work helps deepen understanding of #LongCOVID, a condition still lacking evidence-based treatment options.

So excited to see you all 👍

A cross-sectional study using the UK Biobank cohort suggests middle-aged & older individuals with #migraine may have a reduced burden of cerebral white matter hyperintensities …adachejournal.onlinelibrary.wiley.com/doi/full/10.11… Peng-Peng Niu MD PhD et al

Honored to co-author editorial on non-opioid options for chronic pain. With approval of suzetrigine (NaV1.8 inhibitor), we highlight the urgent need for safer, evidence-based, and multimodal approaches to pain care #ChronicPain #NonOpioid #PainManagement👇 shorturl.at/uo2Nc

I have some patients with refractory VSS. The study might provide insights into their treatment- based on the proposed mechanism.

A warm welcome to Prof. Patricia Pozo-Rosich Patricia Pozo-Rosich to Taiwan! Her inspiring talks on breakthrough on migraine research & biomarker-driven precision medicine at Taipei Veterans General Hospital & #AMTNS deeply resonated with all. Thank you for sharing invaluable insights

Wrapping up April: my son’s birthday party, two talks at the annual meetings of American Academy of Neurology #AANAM and Taiwan Neurological Society, delivered a few other presentations, taught at NCYU, duties of headache societies, and enjoyed a road trip in San Diego.

This study demonstrated the effectiveness of atogepant in preventing migraine after a 12-week treatment in real life conditions. • Only three out of 106 patients discontinued treatment for adverse events. • Moreover, 43% of patients previously resistant to anti-CGRP mAbs

First US population-based survey on CGRP mAb use in migraine now out! Only 5% had ever used them. Top predictors: acute med use, triptan contraindications. Real-world insights to guide personalized care 👉 shorturl.at/uozbx #Migraine #CGRP #Headache Cephalalgia

Favorite Artery?